Scholarlink

<p>Robotic surgery is a game-changing innovation in urology. Novel multiport robotic systems’s (MRS) benefits and limitations in renal surgery when compared to Da Vinci MRS need to be fully understood. This study aims to identify variations from the well-known Da Vinci MRS in terms of surgical, oncological, and functional outcomes in patients undergoing robot-assisted partial nephrectomy (RAPN). Our systematic review and meta-analysis screened Pubmed, Web of Science, and Scopus databases, analyzing data from eighteen papers. Of them, 6 studies compared RAPN outcomes in patients between the novel MRS and Da Vinci MRS. Surgical outcomes (surgical times, estimated blood loss, length of hospital stay, Clavien-Dindo grade &gt; 2 complications rate) and oncological outcomes (positive surgical margins rate and trifecta achievement rate) were analyzed using a Sidik-Jonkman method in a random-effects model. The abovementioned eighteen studies involved and included 1204 patients (631 novel MRS and 573 Da Vinci). Six of them were comparative studies between novel MRS and Da Vinci. Meta-analysis between novel MRS and Da Vinci revealed statistically significant differences in terms of docking time (Mean Difference 1.95; 95% CI 0.41–3.5; I<sup>2</sup> 98.9%; <i>p</i> = 0.01) and console time (Mean Difference 16.72; 95% CI 5.1–28.4; I<sup>2</sup> 67.7%; <i>p</i> &lt; 0.01). No other variations between the two systems were shown in terms of oncological or perioperative results. The present systematic review and meta-analysis demonstrates similar surgical and clinical outcomes for RAPN conducted with the novel MRS and Da Vinci robotic platform, despite the small number of included studies. Novel MRS could be used in resource-limited hospital settings as alternative to Da Vinci MRS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Novel multiport robotic systems versus da vinci multiport robotic system in robot-assisted partial nephrectomy: a systematic review and meta-analysis of surgical and oncological outcomes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月5日

查看全文
  • Francesco Rossi,
  • Maria Chiara Sighinolfi,
  • Filippo Gavi,
  • Marco Montesi,
  • Daniele Fettucciari,
  • Simone Assumma,
  • Enrico Panio,
  • Ela Patel,
  • Francesco Pio Bizzarri,
  • Simona Presutti,
  • Giovanni Battista Filomena,
  • Seyed Koosha Moosavi,
  • Or Schubert,
  • Antonio Silvestri,
  • Giuseppe Pallotta,
  • Pierluigi Russo,
  • Filippo Maria Turri,
  • Riccardo Bientinesi,
  • Mauro Ragonese,
  • Nazario Foschi,
  • Angelo Totaro,
  • Emilio Sacco,
  • Bernardo Rocco

摘要

Robotic surgery is a game-changing innovation in urology. Novel multiport robotic systems’s (MRS) benefits and limitations in renal surgery when compared to Da Vinci MRS need to be fully understood. This study aims to identify variations from the well-known Da Vinci MRS in terms of surgical, oncological, and functional outcomes in patients undergoing robot-assisted partial nephrectomy (RAPN). Our systematic review and meta-analysis screened Pubmed, Web of Science, and Scopus databases, analyzing data from eighteen papers. Of them, 6 studies compared RAPN outcomes in patients between the novel MRS and Da Vinci MRS. Surgical outcomes (surgical times, estimated blood loss, length of hospital stay, Clavien-Dindo grade > 2 complications rate) and oncological outcomes (positive surgical margins rate and trifecta achievement rate) were analyzed using a Sidik-Jonkman method in a random-effects model. The abovementioned eighteen studies involved and included 1204 patients (631 novel MRS and 573 Da Vinci). Six of them were comparative studies between novel MRS and Da Vinci. Meta-analysis between novel MRS and Da Vinci revealed statistically significant differences in terms of docking time (Mean Difference 1.95; 95% CI 0.41–3.5; I2 98.9%; p = 0.01) and console time (Mean Difference 16.72; 95% CI 5.1–28.4; I2 67.7%; p < 0.01). No other variations between the two systems were shown in terms of oncological or perioperative results. The present systematic review and meta-analysis demonstrates similar surgical and clinical outcomes for RAPN conducted with the novel MRS and Da Vinci robotic platform, despite the small number of included studies. Novel MRS could be used in resource-limited hospital settings as alternative to Da Vinci MRS.